At Diamante Società Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotehrapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease. Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects. Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune system’s ability to defend itself; hence reducing potential harmful side effects. We are now seeking funding to cover the next clinical development steps.